“Dr. Harling’s comprehensive clinical experience and tremendous international network within the cancer community is of major importance to 2cureX” says Ole Thastrup, CEO and he continues; “Since the listing of 2cureX at Nasdaq First North Stockholm we have launched multinational clinical trials in three major cancers: colorectal, pancreatic and ovarian. Dr. Harling will be responsible for our present and future clinical activities. I warmly welcome Henrik Harling to 2cureX, and I am convinced that his clinical and managerial expertise will strengthen our team.”
Prior to joining 2cureX, Dr. Harling was Chief of Digestive Disease Center (Surgery and Gastroenterology) at Bispebjerg University Hospital and Associate Professor of Surgery at University of Copenhagen. He established the Danish Colorectal Cancer Database and served as a member of the Executive Board of Danish Multidisciplinary Cancer Groups, Cancer Steering Committee of the National Board of Health and Executive Board of the Danish Society of Cancer. His extensive research also focuses on cancer treatment.
“I have had the pleasure of following 2cureX closely for a number of years as member of the company’s Clinical Advisory Board. I am truly impressed with what the IndiTreat® test can do for very ill cancer patients. I am therefore excited to become a member of the 2cureX team. To help each patient in getting his/her own treatment and to make the society utilize the many medical treatment options in a rational and cost-effective way, so there is for sure a need for 2cureX’s technology” says Henrik Harling.
For more information about 2cureX:
Ole Thastrup, Chief Executive Officer
Telefon: +45 22115399
Telephone: +46 40 615 14 15
This information is information that 2cureX AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on June 20th, 2019.
2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumours that are functionally similar to the patient’s tumour. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.
IndiTreat® is currently being clinically validated in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical studies are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.
The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).